Petros Pharma Changes Auditors to Marcum LLP
Ticker: PTPI · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Petros Pharma swapped auditors from WithumSmith+Brown to Marcum LLP, effective Aug 29.
AI Summary
Petros Pharmaceuticals, Inc. announced on August 29, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, WithumSmith+Brown, PC, and has appointed Marcum LLP as its new principal accountant. This change is effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with other significant corporate events or financial scrutiny.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- WithumSmith+Brown, PC (company) — Former certifying accountant
- Marcum LLP (company) — New certifying accountant
- August 29, 2025 (date) — Effective date of change
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective August 29, 2025.
Who was Petros Pharmaceuticals' previous certifying accountant?
Petros Pharmaceuticals' previous certifying accountant was WithumSmith+Brown, PC.
Who is Petros Pharmaceuticals' new principal accountant?
Petros Pharmaceuticals' new principal accountant is Marcum LLP.
What is the filing date of this Form 8-K?
This Form 8-K was filed on September 5, 2025.
In which state is Petros Pharmaceuticals, Inc. incorporated?
Petros Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 984 words · 4 min read · ~3 pages · Grade level 13.7 · Accepted 2025-09-05 17:00:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The OTCID Basic Market
Filing Documents
- tm2524779d1_8k.htm (8-K) — 29KB
- tm2524779d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-25-087887.txt ( ) — 196KB
- ptpi-20250829.xsd (EX-101.SCH) — 3KB
- ptpi-20250829_lab.xml (EX-101.LAB) — 33KB
- ptpi-20250829_pre.xml (EX-101.PRE) — 22KB
- tm2524779d1_8k_htm.xml (XML) — 4KB
01
Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 29, 2025, the Audit Committee of the Board of Directors (the "Committee") of Petros Pharmaceuticals, Inc. (the "Company") approved the dismissal of CBIZ CPAs P.C. ("CBIZ CPAs") as the Company's independent registered public accounting firm, effective as of the same date. As previously disclosed, CBIZ CPAs acquired the attest business of Marcum, LLP ("Marcum"), the Company's prior independent registered public accounting firm, effective November 1, 2024. Marcum continued to serve as the Company's independent registered public accounting firm through April 5, 2025. On April 5, 2025, the Company terminated its relationship with Marcum as the Company's independent registered accounting firm and, with the approval of the Committee, engaged CBIZ CPAs as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. CBIZ CPAs did not issue any audit report during the period of its engagement. From April 5, 2025 through August 29, 2025, the date of CBIZ CPAs' dismissal, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of CBIZ CPAs, would have caused CBIZ CPAs to make reference to such disagreement in its reports, if such reports had been issued, and (b) no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for the material weakness in the Company's internal control over financial reporting due to a deficiency relating to the Company's insufficient level of monitoring and oversight controls, the size of the Company's accounting and IT departments and appropriate IT access
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from CBIZ CPAs P.C. to the Securities and Exchange Commission dated September 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Petros pharmaceuticals, Inc . Date: September 5, 2025 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer